Siemens’ PETNET Solutions to Offer PET Prostate Tracer for Clinical Trials

Published on:

In an effort to support positron emission tomography (PET) imaging techniques for the diagnosis and treatment of prostate cancer, Siemens’ PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, will provide clinical researchers in the greater New York City area with access to Gallium-68-Labelled Prostate-Specific Membrane Antigen (68Ga-labelled PSMA). This investigational tracer is being studied for prostate cancer imaging using PET/computed tomography (PET/CT) in clinical trials throughout the world.

Prostate cancer is the second most frequently diagnosed cancer among men in the United States. An estimated 220,000 men are expected to be diagnosed with the disease this year, with approximately 15,000 in New York state alone.¹ Recent hypotheses regarding the variation and diversity of prostate cancer suggest that all variants should not be treated equally² – underscoring a need for expanded classification of the disease through  imaging and biopsy methods.

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.